Anti-GAD65 Antibodies Related Refractory Epilepsy Successfully Treated with Tocilizumab: A Case Report and Systematic Literature Review
ImmunoTargets and Therapy · 2025-04 · Volume 14 · 491-500
DOI: 10.2147/itt.s520026 ↗Kurz gefasst
Fallbericht in der Zeitschrift ImmunoTargets and Therapy, 2025-04. Verfasst von Shimeng Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, People's Republic of China. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
- Hunan Intellectual and Developmental Disabilities Research Center, Pediatrics, Changsha, People's Republic of China.
- Clinical Research Center for Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
ORCID-Profile: Miriam Kessi, Fang He, Fei Yin, Lifen Yang, Jing Peng
Zitieren
APA
Chen, S., Kessi, M., Tan, J., He, F., Zhang, C., Yin, F., Yang, L., & Peng, J. (2025). Anti-GAD65 Antibodies Related Refractory Epilepsy Successfully Treated with Tocilizumab: A Case Report and Systematic Literature Review. ImmunoTargets and Therapy, Volume 14, 491-500. https://doi.org/10.2147/itt.s520026
Vancouver
Chen S, Kessi M, Tan J, He F, Zhang C, Yin F, et al. Anti-GAD65 Antibodies Related Refractory Epilepsy Successfully Treated with Tocilizumab: A Case Report and Systematic Literature Review. ImmunoTargets and Therapy. 2025;Volume 14:491-500. doi:10.2147/itt.s520026
BibTeX
@article{Chen2025,
author = {Chen, Shimeng and Kessi, Miriam and Tan, Jielu and He, Fang and Zhang, Ciliu and Yin, Fei and Yang, Lifen and Peng, Jing},
title = {Anti-GAD65 Antibodies Related Refractory Epilepsy Successfully Treated with Tocilizumab: A Case Report and Systematic Literature Review},
journal = {ImmunoTargets and Therapy},
year = {2025},
volume = {Volume 14},
pages = {491--500},
doi = {10.2147/itt.s520026}
}
EUVIMED